Lobe Sciences (LOBEF)
OTHER OTC:LOBEF
LOBEF Stock Chart & Stats
$0.04
>-$0.01(-17.06%)
At close: 4:00 PM EST
$0.04
>-$0.01(-17.06%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume171.00
Average Volume (3M)103.94K
Market Cap
$14.68M
Enterprise Value$11.69M
Total Cash (Recent Filing)$7.02M
Total Debt (Recent Filing)$295.68K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding269,487,120
10 Day Avg. Volume62,263
30 Day Avg. Volume103,939
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized R&D FocusA focused therapeutic strategy targeting psychedelic-derived treatments establishes a clear, durable business model in a high-barriers segment of mental health R&D. Specialization supports deep domain expertise, potential regulatory pathways, and differentiated IP that can sustain long-term clinical value if trials progress.
Low LeverageModest leverage and very low absolute debt materially reduce near-term solvency and interest burden risks. This balance-sheet position preserves optionality to fund R&D through equity or partnerships rather than servicing large debt, a durable advantage while the company advances clinical programs.
Improving Free Cash Flow TrendAn improving free cash flow trajectory, even from negative levels, signals early operational progress or tighter spending controls. Sustained improvement over quarters provides a durable signal that cash burn can be managed lower, extending runway and reducing frequency of external capital raises.
Bears Say
Minimal Revenue And Large LossesNear-zero trailing revenue and multi-million dollar operating losses indicate the company is not at commercial scale and remains dependent on development-stage economics. This structural lack of recurring revenue makes long-term viability contingent on successful clinical outcomes or external financing.
Persistent Cash BurnRepeated negative operating and free cash flow show the business consumes cash to sustain R&D and operations. Persisting cash burn constrains investment flexibility, increases financing dependency, and creates execution risk if capital markets tighten or partnership timelines slip.
Historical Equity Instability / Financing RelianceHistoric swings into negative equity and asset growth tied to financing point to past dependence on non-operating capital raises and restructurings. This pattern raises the structural risk of dilution, governance stress, and repeated recapitalizations until operations generate sustainable cash flow.
Lobe Sciences News
LOBEF FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was $0.01 and its highest was $0.08 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is $14.68M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 40 days.
How were Lobe Sciences’s earnings last quarter?
Currently, no data Available
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 269,487,120 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in LOBEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Ownership Overview
Options Prices
Currently, No data available
---